Mark Andreozzi, DO
Otolaryngology · Warwick, RINPI 1487701975
Payments from drug & device makers
Across 605 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Optinose US, Inc.$657
- AbbVie$540
- plus $4K from 27 others
What the payments were for
- Food & beverage$14,778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 125 | $3,750 |
| GSK | 100 | $2,309 |
| Sanofi | 68 | $2,006 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,468 |
| Optinose US, Inc. | 42 | $657 |
| AbbVie(2 entities) | 28 | $540 |
| Pfizer | 33 | $505 |
| Genentech USA, Inc. | 25 | $480 |
| Novartis | 18 | $323 |
| Kaleo, Inc. | 17 | $276 |
| Stryker | 5 | $270 |
| Intersect ENT, Inc. | 4 | $246 |
| Teva Pharmaceuticals USA, Inc. | 16 | $206 |
| Acclarent, Inc | 4 | $175 |
| Boehringer Ingelheim | 4 | $174 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $169 |
| Inspire Medical Systems, Inc. | 1 | $169 |
| Alk-abello, Inc | 8 | $132 |
| Biohaven Pharmaceuticals, Inc. | 16 | $132 |
| Amgen | 3 | $131 |
| Merck | 1 | $124 |
| Puma Biotechnology, Inc. | 1 | $104 |
| Smith+Nephew | 4 | $83 |
| Hikma Pharmaceuticals USA | 4 | $67 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $67 |
| Aerin Medical Inc. | 3 | $48 |
| Medtronic | 2 | $31 |
| Watermark Medical, Inc. | 2 | $30 |
| Pharming Healthcare, Inc. | 1 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| LEO Pharma Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$831
- FASENRA$467
- NUCALA$460
- TEZSPIRE$359
- Inspire$169
- ENTELLUS - XPRESS ENT DILATION SYSTEM$139
- PROPEL$132
- BREZTRI$125
- ACCLARENT Balloon Inflation Device$122
- AREXVY$109
- AIRSUPRA$108
- Nerlynx$104
- SYMBICORT$104
- BEVESPI AEROSPHERE$104
How this compares
$14,778 in reported general payments places this provider in the 95th percentile of 23 otolaryngology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 62 | $186,554 |
| XhanceFluticasone Propionate | 31 | $18,628 |
| Ipratropium Bromide | 332 | $18,349 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,464 |
| Fluticasone Propionate | 509 | $9,884 |
| Arnuity ElliptaFluticasone Furoate | 29 | $9,771 |
| Azelastine Hcl | 266 | $8,841 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,302 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,616 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,575 |
| Epinephrine | 18 | $2,287 |
| Montelukast Sodium | 73 | $868 |
| Ventolin HfaAlbuterol Sulfate | 12 | $743 |
| Omeprazole | 62 | $692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $2,309 | $36,51780 claims |
| Optinose US, Inc.Xhance | $657 | $18,62831 claims |
| AstraZenecaSymbicort | $3,750 | $3,30213 claims |
| Hikma Pharmaceuticals USAEpinephrine | $67 | $2,28718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 otolaryngology providers in Rhode Island.
Other otolaryngology in Warwick
- Alejandro VazquezWarwick$10K
- Amit PatelWarwick$7K
- Barbara GuilletteWarwick$4K
- George JacewiczWarwick$0
- Frederick GodleyProvidence$96K
- David CameronWesterly$7K
- Jeffrey FeldmanWesterly$4K
- John TarroProvidence$4K
- Eugene StecWesterly$4K
- Prabhakar TipirneniWakefield$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.